Table 1.

Baseline characteristics of participants with type 2 diabetes and CKD in a clinical trial of esaxerenone (efficacy full analysis set)

Clinical Characteristics/Prior TreatmentPlacebo, n=73Esaxerenone 0.625 mg/d, n=71Esaxerenone 1.25 mg/d, n=72Esaxerenone 2.5 mg/d, n=70Esaxerenone 5 mg/d, n=72All, n=358
Sex, men57 (78)54 (76)54 (75)57 (81)57 (79)279 (78)
Age, yr66±1066±966±864±1165±965±9
Weight, kg70±1569±1268±1570±1269±1369±13
Body mass index, kg/m225.9±4.225.8±3.625.7±3.926.0±4.125.6±3.825.8±3.9
Sitting systolic BP, mm Hg138±11138±11139±10137±13136±12138±11
Sitting diastolic BP, mm Hg76±976±976±877±976±976±9
UACR (mg/g Cr), geometric mean (95% CI)110 (98 to 123)104 (92 to 116)111 (98 to 125)112 (100 to 126)110 (101 to 126)110 (104 to 115)
HbA1c, %6.9±0.66.8±0.76.8±0.77.0±0.66.9±0.66.9±0.6
Serum K+, mEq/L4.3±0.34.2±0.34.3±0.34.3±0.34.2±0.34.3±0.3
eGFR, ml/min per 1.73 m269±1966±1466±1868±1969±1867±18
LDL cholesterol, mg/dl109±28101±28107±29107±30109±31107±29
Duration of diabetes, yr14±914±916±1016±1214±815±10
Other diabetic complications29 (40)34 (48)39 (54)35 (50)36 (50)173 (48)
Hypertension71 (97)68 (96)70 (97)68 (97)68 (94)345 (96)
Hyperlipidemia56 (77)56 (79)53 (74)52 (74)53 (74)270 (75)
Cardiac disorder14 (19)10 (14)13 (18)9 (13)13 (18)59 (17)
Other antihypertensive agents
 Calcium channel blocker47 (64)47 (66)47 (65)43 (61)47 (65)231 (65)
 Diuretics8 (11)8 (11)14 (19)8 (11)7 (10)45 (13)
Antihypertensive agents
 ARB71 (97)69 (97)70 (97)67 (96)71 (99)349 (97)
 ACEi2 (3)2 (3)2 (3)3 (4)1 (1)10 (3)
No. of antihypertensive agents
 Monotherapy25 (34)19 (27)20 (28)24 (34)22 (31)110 (31)
 Double therapy30 (41)36 (51)32 (44)34 (49)32 (44)164 (46)
 Triple therapy or more18 (25)16 (23)20 (28)12 (17)18 (25)84 (24)
HMG-CoA reductase inhibitor38 (52)31 (44)31 (43)38 (54)31 (43)169 (47)
Hypoglycemic agent68 (93)61 (86)64 (89)62 (89)57 (79)312 (87)
DPP4 inhibitor48 (66)44 (62)44 (61)46 (66)46 (64)228 (64)
SGLT2 inhibitor3 (4)3 (4)4 (6)10 (14)6 (8)26 (7)
  • Data are n (%) or mean ± SD unless otherwise stated. UACR, urinary albumin-to-creatinine ratio; Cr, creatinine; 95% CI, 95% confidence interval; HbA1c, glycated hemoglobin; K+, potassium; ARB, angiotensin receptor blocker; ACEi, angiotensin-converting enzyme inhibitor; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2.